Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM.
Alsina M, et al. Among authors: cantor ab.
Blood. 2004 May 1;103(9):3271-7. doi: 10.1182/blood-2003-08-2764. Epub 2004 Jan 15.
Blood. 2004.
PMID: 14726402
Free article.
Clinical Trial.